IL6 and ovarian carcinoma: Conversely, SIK3 demonstrates a dual role: it promotes cell proliferation in breast and ovarian cancers by facilitating the G1/S transition, but inhibits proliferation in non‐small cell lung cancer (NSCLC) through modulation of AP1 and IL6 signaling.